📰 Clinical Development News
Page 72 - Clinical Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Development. Real-time updates on events, politics, business and more.
October 31, 2023
Integrated drug discovery contract research organization (CRO) Sygnature Discovery has invested £3.75 million in an Azenta compound management storage system that can also provide customer libraries.
October 31, 2023
It was announced today (October 31), that the US Food and Drug Administration (FDA) has granted permission to proceed with clinical investigations of small molecule treatment, roginolisib.
October 30, 2023
TAIPEI, Oct. 30, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today that the company will be presenting at the American
October 30, 2023
Continuous flow manufacturing is taking off in the production of active pharmaceutical ingredients (APIs).
October 27, 2023
ICON Public Limited Company (NASDAQ:ICLR) Q3 2023 Earnings Call Transcript October 26, 2023 Kate Haven: Good day, and thank you for joining us on this call covering the quarter ended September 30, 2023. Also on the call today, we have our CEO, Dr. Steve Cutler; and our CFO, Mr. Brendan Brennan. I would like to […]
October 26, 2023
Company Updates Full-Year Guidance Third quarter revenue grew 6.6% versus last year as the Base Business grew 14.0%. Results from Continuing Operations for...
October 26, 2023
26.10.2023 - — Clinical responses with TransCon IL-2 β⁄γ demonstrated as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination therapy — TransCon IL-2 β⁄γ administered every ... Seite 1
October 25, 2023
She has a proven track record of leading and mentoring start-ups in the biotechnology field, with her proven abilities in investment and portfolio management, investments, risk management, and business strategy development, Maria is a go-to expert in the industry.
October 24, 2023
(2023-10-24 | NDAQ:APRE) Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
October 24, 2023
- THN391 was found to be safe and well-tolerated -- THN391 demonstrated a prolonged half-life and dose proportional Cmax levels -- The data will be...